Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ATGL Lentiviral Activation Particles (h): sc-401711-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- ATGL Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- ATGL Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by ATGL Lentiviral Activation Plasmid (h) and ATGL Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the PNPLA2 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: ATGL Antibody (F-7): sc-365278
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ATGL Lentiviral Activation Particles (h) | sc-401711-LAC | 200 µl | $455.00 | |||
ATGL Lentiviral Activation Particles (h2) | sc-401711-LAC-2 | 200 µl | $455.00 |
Human PNPLA2 encodes adipose triglyceride lipase (ATGL), the rate-limiting enzyme for the first step of triacylglycerol hydrolysis on lipid droplets, generating diacylglycerol and free fatty acids for β-oxidation and lipid signaling. ATGL activity integrates with lipid droplet biogenesis, lipophagy, and PPAR-dependent transcriptional programs that coordinate energy homeostasis across metabolic tissues. Perturbation of PNPLA2/ATGL alters intracellular lipid storage, mitochondrial substrate availability, and inflammatory lipid mediator balance. Dysregulated ATGL function has been linked to ectopic lipid accumulation and cardiometabolic phenotypes, supporting its use as a mechanistic node in studies of lipotoxicity and metabolic remodeling.
ATGL Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient PNPLA2 upregulation across a broader range of human cell types.
ATGL Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the PNPLA2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous ATGL expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native PNPLA2 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.